NCT07230015 Combined Motor Imagery and Vestibular Rehab for MS
| NCT ID | NCT07230015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medipol University |
| Condition | Multiple Sclerosis (MS) - Relapsing-remitting |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial investigates the first combined use of motor imagery and vestibular rehabilitation in multiple sclerosis, aiming to evaluate their joint effect on balance, cognition, and quality of life.
Eligibility Criteria
inclusion criteria 1. Diagnosis of Multiple Sclerosis (MS) Confirmed using McDonald Criteria 2. Patient diagnosed relapsing-remitting multiple sclerosis (RRMS). 3. Mild MS between 0-3 according to PDDS. 4. Age from (18-45) 5. Mild cognitive impairment 6. Balance impairment (mild to moderate impairment) 7. Vestibular dysfunction Related to MS (dizziness, vertigo , gaze instability ) 8. Native language is Arabic to ensure clear communication during cognitive tasks and exercise instructions 9\. Be able to joined the treatment (motor imagery, vestibular rehabilitaiton ) Exclusion Criteria: Other neurological disorder, progressive multiple sclerosis Non-MS related vestibular disorders (e.g., BPPV, Meniere's disease) that would interfere with vestibular rehab. Severe Psychiatric Conditions (schizophrenia, bipolar, etc) Sever balance disorder Sever fatigue Medical instability eg (cardiovascular disease, respiratory, infections, severe uncontrolled diabetes, or severe visual impairments.) Sever cognitive impairment Pregnant Advance disability ( wheelchair , unable to stand ) Use of Vestibular-Suppressing Medications Non - speaker Arabic
Contact & Investigator
Merve Yılmaz Menek, Assoc. Prof
STUDY DIRECTOR
Assoc. Prof. Merve Yılmaz Menek
Frequently Asked Questions
Who can join the NCT07230015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Multiple Sclerosis (MS) - Relapsing-remitting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07230015 currently recruiting?
Yes, NCT07230015 is actively recruiting participants. Contact the research team at j.menshawi@hotmail.com for enrollment information.
Where is the NCT07230015 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07230015 clinical trial?
NCT07230015 is sponsored by Medipol University. The principal investigator is Merve Yılmaz Menek, Assoc. Prof at Assoc. Prof. Merve Yılmaz Menek. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.